Cargando…
Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan
BACKGROUND: No data on the long-term ‘real-world’ use of fluvoxamine for the treatment of social anxiety disorder (SAD) in Japanese patients are currently available. OBJECTIVE: To evaluate the long-term safety and efficacy of fluvoxamine for SAD in the clinical setting. METHODS: Japanese patients wi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883186/ https://www.ncbi.nlm.nih.gov/pubmed/27747476 http://dx.doi.org/10.1007/s40801-014-0005-2 |
_version_ | 1782434226679840768 |
---|---|
author | Asakura, Satoshi Koyama, Tsukasa Hosokai, Takeshi Kawano, Hitoshi Kajii, Yasushi |
author_facet | Asakura, Satoshi Koyama, Tsukasa Hosokai, Takeshi Kawano, Hitoshi Kajii, Yasushi |
author_sort | Asakura, Satoshi |
collection | PubMed |
description | BACKGROUND: No data on the long-term ‘real-world’ use of fluvoxamine for the treatment of social anxiety disorder (SAD) in Japanese patients are currently available. OBJECTIVE: To evaluate the long-term safety and efficacy of fluvoxamine for SAD in the clinical setting. METHODS: Japanese patients with SAD who initiated treatment with fluvoxamine were enrolled in this 53-week post-marketing survey from 407 institutions nationwide. Data including rates of adverse drug reactions (ADRs) and efficacy were collected. Overall improvement was assessed using the Clinical Global Impression for Improvement. SAD symptoms and treatment responses were assessed with the Japanese version of the Liebowitz Social Anxiety Scale. RESULTS: From the 1,974 patients surveyed, 1,790 and 1,504 patients were eligible for analysis of safety and efficacy, respectively. ADRs were reported in 18.2 % of patients, with nausea, somnolence, and constipation the most common. Over 50 % of these ADRs developed in the first 4 weeks of treatment. Serious ADRs were reported in 0.8 % of patients and included six cases of suicide attempt and three cases of suicidal ideation. Response to fluvoxamine was reported in 78.4 % of patients. In patients comorbid with depression, improvement in SAD symptoms with fluvoxamine treatment was significantly affected by clinical improvement in the depression. CONCLUSIONS: These findings support the long-term safety and efficacy of fluvoxamine in patients with SAD. Most ADRs developed during the early treatment phase, and higher doses during the later phase were not associated with an increase in ADRs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40801-014-0005-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4883186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-48831862016-08-19 Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan Asakura, Satoshi Koyama, Tsukasa Hosokai, Takeshi Kawano, Hitoshi Kajii, Yasushi Drugs Real World Outcomes Original Research Article BACKGROUND: No data on the long-term ‘real-world’ use of fluvoxamine for the treatment of social anxiety disorder (SAD) in Japanese patients are currently available. OBJECTIVE: To evaluate the long-term safety and efficacy of fluvoxamine for SAD in the clinical setting. METHODS: Japanese patients with SAD who initiated treatment with fluvoxamine were enrolled in this 53-week post-marketing survey from 407 institutions nationwide. Data including rates of adverse drug reactions (ADRs) and efficacy were collected. Overall improvement was assessed using the Clinical Global Impression for Improvement. SAD symptoms and treatment responses were assessed with the Japanese version of the Liebowitz Social Anxiety Scale. RESULTS: From the 1,974 patients surveyed, 1,790 and 1,504 patients were eligible for analysis of safety and efficacy, respectively. ADRs were reported in 18.2 % of patients, with nausea, somnolence, and constipation the most common. Over 50 % of these ADRs developed in the first 4 weeks of treatment. Serious ADRs were reported in 0.8 % of patients and included six cases of suicide attempt and three cases of suicidal ideation. Response to fluvoxamine was reported in 78.4 % of patients. In patients comorbid with depression, improvement in SAD symptoms with fluvoxamine treatment was significantly affected by clinical improvement in the depression. CONCLUSIONS: These findings support the long-term safety and efficacy of fluvoxamine in patients with SAD. Most ADRs developed during the early treatment phase, and higher doses during the later phase were not associated with an increase in ADRs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40801-014-0005-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2014-10-30 /pmc/articles/PMC4883186/ /pubmed/27747476 http://dx.doi.org/10.1007/s40801-014-0005-2 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Article Asakura, Satoshi Koyama, Tsukasa Hosokai, Takeshi Kawano, Hitoshi Kajii, Yasushi Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan |
title | Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan |
title_full | Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan |
title_fullStr | Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan |
title_full_unstemmed | Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan |
title_short | Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan |
title_sort | post-marketing surveillance of fluvoxamine maleate used long-term in patients with social anxiety disorder in japan |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883186/ https://www.ncbi.nlm.nih.gov/pubmed/27747476 http://dx.doi.org/10.1007/s40801-014-0005-2 |
work_keys_str_mv | AT asakurasatoshi postmarketingsurveillanceoffluvoxaminemaleateusedlongterminpatientswithsocialanxietydisorderinjapan AT koyamatsukasa postmarketingsurveillanceoffluvoxaminemaleateusedlongterminpatientswithsocialanxietydisorderinjapan AT hosokaitakeshi postmarketingsurveillanceoffluvoxaminemaleateusedlongterminpatientswithsocialanxietydisorderinjapan AT kawanohitoshi postmarketingsurveillanceoffluvoxaminemaleateusedlongterminpatientswithsocialanxietydisorderinjapan AT kajiiyasushi postmarketingsurveillanceoffluvoxaminemaleateusedlongterminpatientswithsocialanxietydisorderinjapan |